Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study

(2014) Gonzalo Díaz-Soto et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

(2014) D Shyangdan et al.   HEALTH TECHNOLOGY ASSESSMENT

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer

(2014) James D. Lewis et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2013) Lesley J. Scott   BIODRUGS

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

(2013) Bo Ahrén et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

(2013) Matthew C. Riddle et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

(2013) Matthew C. Riddle et al.   DIABETES CARE

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)

(2013) M. Pinget et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

(2013) G. B. Bolli et al.   DIABETIC MEDICINE

Potential of incretin-based therapies for non-alcoholic fatty liver disease

(2013) Susan L. Samson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

The burden of liver disease in Europe: A review of available epidemiological data

(2013) Martin Blachier et al.   JOURNAL OF HEPATOLOGY

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

(2013) Martin Lorenz et al.   REGULATORY PEPTIDES

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

(2013) Yutaka Seino et al.   Journal of Diabetes Investigation

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for Practice

(2012) Gavin B. Stewart et al.   PLoS One

Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease

(2012) Neven Baršić   WORLD JOURNAL OF GASTROENTEROLOGY

Lixisenatide for type 2 diabetes mellitus

(2011) Mikkel Christensen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease

(2011) Michael H. Miller et al.   LIVER INTERNATIONAL

Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease

(2010) J. Estep et al.   CURRENT MOLECULAR MEDICINE

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

(2009) John Dormandy et al.   DRUG SAFETY